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The host innate response to viral infection includes the production of interferons, which is dependent on the coordinated activity of multiple
transcription factors. Herpes simplex virus 1 (HSV-1) has been shown to block efficient interferon expression by multiple mechanisms. We and
others have demonstrated that HSV-1 can inhibit the transcription of genes promoted by interferon regulatory factor-3 (IRF-3), including
interferon beta (IFN-β), and that the immediate–early ICP0 protein is sufficient for this function. However, the exact mechanism by which ICP0
blocks IRF-3 activity has yet to be determined. Unlike some other viral proteins that inhibit IRF-3 activity, ICP0 does not appear to affect
phosphorylation and dimerization of IRF-3. Here, we show that a portion of activated IRF-3 co-localizes with nuclear foci containing ICP0 at early
times after virus infection. Co-localization to ICP0-containing foci is also seen with the IRF-3-binding partners and transcriptional co-activators,
CBP and p300. In addition, using immunoprecipitation of infected cell lysates, we can immunoprecipitate a complex containing ICP0, IRF-3, and
CBP. Thus we hypothesize that ICP0 recruits activated IRF-3 and CBP/p300 to nuclear structures, away from the host chromatin. This leads to the
inactivation and accelerated degradation of IRF-3, resulting in reduced transcription of IFN-β and an inhibition of the host response. Therefore,
ICP0 provides an example of how viruses can block IFN-β induction by sequestration of important transcription factors essential for the host
response.
© 2006 Elsevier Inc. All rights reserved.Keywords: Innate immunity; Immune evasionIntroduction
Innate immune responses to viral infection are multi-step
processes requiring the recognition of virus infection, activation
of multiple signal transduction cascades, and the transcription of
antiviral genes. One of the most important proteins produced
following infection, and a critical component of the innate
immune response, is interferon beta (IFN-β). IFN-β is a
cytokine that acts in an autocrine and paracrine manner to up-
regulate the expression of a number of cellular proteins with
anti-viral activity (Biron and Sen, 2001). Expression of IFN-β is
an essential component of the innate immune response to viral
infection, as demonstrated by studies in animals and humans
that have defects in the ability to make or respond to interferons
(Dupuis et al., 2003; Hwang et al., 1995; Muller et al., 1994).
The importance of interferon production to host defense is also⁎ Corresponding author. Fax: +1 617 432 0223.
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doi:10.1016/j.virol.2006.10.028apparent from the number of ways in which viruses have
evolved to inhibit this response.
Because there are multiple proteins involved in the signaling
pathways that lead to IFN-β production, viruses have many
opportunities to target cellular proteins for inhibition. Some
viruses can block recognition of viral infection by inhibiting the
signaling from Toll-like receptors (TLRs) or other pattern
recognition receptors. For example, vaccinia virus and hepatitis
C virus can interfere with the signaling of TLR-interacting
proteins (Li et al., 2005; Stack et al., 2005; Unterstab et al.,
2005). Another efficient way that viruses block the initial
transcription of IFN-β is to inhibit the activity of a crucial
transcription factor, interferon regulatory factor-3 (IRF-3).
Functional IRF-3 is absolutely required for the immediate
transcription of interferon resulting from virus infection (Sato
et al., 2000; Yeow et al., 2001). Activation of IRF-3 requires
phosphorylation of the C-terminus by one of the IκB kinase
(IKK)-related kinases, IKKε or TANK-binding kinase 1
(Fitzgerald et al., 2003; Sharma et al., 2003). Following
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modifications in the process of localizing to the nucleus and
associating with the CBP/p300 acetyltransferase (Wathelet et al.,
1998; Yang et al., 2002, 2004; Yoneyama et al., 1998). IRF-3
signaling is inhibited by a wide variety of viruses at one or more
steps in the activation pathway. Viruses have been shown to
inhibit phosphorylation (Basler et al., 2003; Brzozka et al., 2005;
Foy et al., 2003), dimerization (Jennings et al., 2005), nuclear
translocation (Donelan et al., 2004), interaction with CBP/p300
(Burysek et al., 1999; Chakravarti et al., 1999; Jennings et al.,
2005), or to decrease the cellular levels of IRF-3 (Barro and
Patton, 2005; La Rocca et al., 2005). Understanding the
mechanisms by which viruses inhibit IRF-3 provides insight
into how viruses block the interferon response, and ultimately, of
how viruses replicate successfully.
Herpes simplex virus 1 (HSV-1) is a common human
pathogen that can lytically infect epithelial cells and establish
latency in neurons. Soon after infection, the VP16 (α-TIF)
protein stimulates the transcription of the five immediate–early
(IE) genes; ICP0, −4, −22, −27, and −47 (Batterson and
Roizman, 1983; Campbell et al., 1984; Spear and Roizman,
1972). Like other viruses, HSV-1 activates the innate immune
response through interactions with TLRs on the host cell (Krug
et al., 2004; Kurt-Jones et al., 2004; Lund et al., 2003). HSV-1
activates IRF-3 in a cell-type-dependent manner (Preston et al.,
2001). However, activation of the immune response is far more
robust in the absence of viral IE protein synthesis (Mossman et
al., 2001; Nicholl et al., 2000; Preston et al., 2001). Pretreatment
of cells with interferons has been shown to decrease the
expression of IE genes, and thus blocks viral replication
(Mittnacht et al., 1988; Oberman and Panet, 1988, 1989).
Multiple studies have demonstrated that the immediate–
early protein ICP0 can inhibit transcription regulated by IRF-3,
thereby decreasing host interferon production and attenuating
the innate immune response (Eidson et al., 2002; Lin et al.,
2004; Melroe et al., 2004). We investigated the mechanism by
which HSV-1 could inhibit the activity of IRF-3 induced
following activation by another virus. We previously used
Sendai virus (SeV) to activate the IRF-3 signaling pathway and
generate IFN-β (Melroe et al., 2004).We determined that HSV-1
infection can inhibit the production of interferon induced by SeV
infection in HEC-1-B cells. This inhibition is enhanced by the
presence of ICP0, but ICP0 is not required for this effect. We
observed that the presence of ICP0 causes increased degradation
of activated IRF-3 following SeV infection. In addition,
activated IRF-3 does not efficiently accumulate in the nucleus
of infected cells at late times post-infection in the presence of
ICP0, perhaps as a consequence of the increased degradation.
Studies byMossman's group demonstrated that HSV-1 infection
can block the transcription from interferon-stimulated gene
(ISG)-specific promoters (Lin et al., 2004). In their system,
HSV-1 infection of A549 cells, IRF-3 fails to become hyperpho-
sphorylated and activated following HSV-1 infection. Thus, the
ICP0-enhanced destabilization of IRF-3 may involve activated
and/or nuclear IRF-3.
In these studies, we further investigated the effects of ICP0
production on IRF-3 activity after phosphorylation, dimeriza-tion, and nuclear accumulation. We focused our investigation on
ICP0 by using the d106 HSV-1 mutant virus, which expresses
ICP0 and no other IE protein (Samaniego et al., 1998). In
addition, we used a panel of ICP0 nonsense mutants to
determine the regions required for IRF-3 inhibition. We
observed a change in the normal localization patterns of IRF-3
and the IRF-3-binding partner, CBP/p300, following d106
infection and ICP0 production. These cellular proteins, required
for efficient interferon transcription, localize to punctate nuclear
domains that contain ICP0. These results suggest that ICP0
functions, in part, to sequester certain cellular proteins required
for efficient IFN-β gene transcription. We propose that this
sequestration affects the ability of IRF-3 and CBP/p300 to
promote the transcription of cellular genes, resulting in a sub-
optimal interferon response.
Results
ICP0 expressed by d106 can enhance the degradation of IRF-3
We observed previously that activation of IRF-3 in the
presence of ICP0 leads to increased IRF-3 degradation (Melroe
et al., 2004). To determine if ICP0 was sufficient for this
observed loss of IRF-3, we used the HSV-1 d106 virus
(Samaniego et al., 1998), which expresses ICP0 in the absence
of other viral IE proteins and can block interferon induction
(Eidson et al., 2002; Melroe et al., 2004).
We first examined IRF-3 levels in cells infected with SeV,
d106, or both. At 2 and 4 h post SeV infection, IRF-3 showed
decreased mobility but constant levels (Fig. 1, lanes 2 and 3).
However, by 6 and 8 h post-infection (hpi), the amount of IRF-3
began to decrease (Fig. 1, lanes 6 and 8). With cells infected
with both SeV and d106, we saw a greater decrease in levels of
IRF-3 at 6 and 8 hpi (Fig. 1, lanes 5 and 7). The quantification
shown is representative of results obtained from multiple
experiments. This decrease in IRF-3 levels was similar to what
we observed previously when we infected cells with SeV and
wild-type HSV-1 (Melroe et al., 2004). We also observed
decreased levels of DNA-PKcs (Fig. 1, lanes 5 to 7), a protein
whose degradation is promoted by ICP0 (Lees-Miller et al.,
1996; Parkinson et al., 1999). The levels of NF-κB p65 subunit
remained constant (Fig. 1).
We next examined the levels and distribution of IRF-3 by
using an antibody that recognizes nuclear IRF-3 (Melroe et al.,
2004). In SeV-infected cells, IRF-3 accumulated in the nucleus
by 2 hpi, but decreased over time (Fig. 1B, a to e). In cells co-
infected with SeV and d106, nuclear IRF-3 was apparent by
2 hpi but then decreased by 4 hpi (Fig. 1B, g to j),
consistent with our Western blot data. At 2 hpi, activated
IRF-3 appeared to have two distinct localization patterns
depending on the infection condition. In cells infected with
SeV alone, IRF-3 was largely diffuse (Fig. 1B, b). In
contrast, in cells co-infected with SeV and d106, much of
the IRF-3 was localized to a number of punctate structures at
2 hpi (Fig. 1B, g).
These results indicated that ICP0, in the absence of the other
IE proteins, can accelerate the degradation of activated IRF-3.
Fig. 1. IRF-3 levels are reduced in d106-infected cells. (A) Western blot showing total levels of IRF-3 at different time points post-infection following exposure to SeV
in the presence or absence of d106. Proteins in cell lysates were separated by SDS–PAGE and detected with antibodies towards DNA-PKcs, NF-κB (p65 subunit), or
IRF-3. Individual bands corresponding to the proteins were scanned, and the intensity was quantified by computer analysis. The protein amounts were normalized to
the amount present in mock-infected cells. The data presented are representative of multiple experiments. (B) Indirect immunofluorescence was used to determine the
localization and relative amount of IRF-3 at different time points post-infection. After fixation, the cells were incubated with the SL12.1 antibody to IRF-3, followed by
an Alexa Fluor 488 goat anti-mouse secondary antibody. Image exposure time was set by using the SeV-infected cells at 4 hpi and was kept constant in the other
samples.
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change in the distribution of IRF-3 at early times after
activation.
Co-localization of ICP0, activated IRF-3, and CBP/p300 at
early times post-infection
ICP0 promotes the degradation of a variety of proteins in the
host cell (Hagglund and Roizman, 2004). Many cellular
proteins affected by ICP0 have been found to localize to
similar nuclear domains following infection, while not
necessarily binding directly to ICP0 (Burch and Weller, 2004;
Lomonte et al., 2004). We wished to investigate possible
mechanisms by which ICP0 could affect the degradation andnuclear accumulation of IRF-3 that we observed. To determine
if IRF-3 co-localized with ICP0 at early times post-infection, we
examined the distribution of the two proteins by immunofluor-
escence microscopy. SeV infection caused IRF-3 to accumulate
in the nucleus (Fig. 2A, b). Cells infected with d106 alone
showed no nuclear IRF-3, and therefore no co-localization with
ICP0 (not shown). Following infection with both d106 and SeV,
we observed IRF-3 in punctate nuclear structures (Fig. 2A, c).
These areas of enhanced IRF-3 accumulation overlapped with
the staining for nuclear ICP0 (Fig. 2A, f), but not all nuclear
ICP0 co-localized with the nuclear IRF-3 (Fig. 2A, i). In
addition, there was still a noticeable amount of diffuse IRF-3 not
found in the ICP0-containing foci at these early times. These
data showed that, following activation, a fraction of nuclear
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Fig. 2. Change of IRF-3 localization in the presence of ICP0. HEC-1-B cells were infected with SeV in the presence or absence of d106. (A) The cells were fixed at
2.5 hpi and stained with mouse anti-ICP0 and rabbit anti-IRF-3 antibodies followed by appropriate secondary antibodies. (B) The cells were stained with mouse anti-
p300 and rabbit anti-IRF-3 antibodies followed by appropriate secondary antibodies. (C) The cells were stained with mouse anti-CBP and rabbit anti-IRF-3 antibodies
followed by appropriate secondary antibodies.
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bodies.
Upon entering the nucleus, the activated IRF-3 dimer
associates with transcriptional co-activators, either CBP or
p300 (Sato et al., 1998; Wathelet et al., 1998; Yoneyama et al.,
1998). Because this association follows IRF-3 activation, we
determined the localization of CBP and p300 to see if ICP0
could influence IRF-3 co-localization with CBP/p300. To
examine the localization of CBP and p300 following infection,
we performed immunofluorescence microscopy using mono-
clonal antibodies specific for p300 (RW128) or CBP (AC238).
The p300 monoclonal antibody was very effective at staining
the nuclei of cells (Fig. 2B, a). Infection of cells with SeValone
did not change the nuclear distribution of p300 (Fig. 2B, b).
Following d106 co-infection with SeV, we observed that IRF-3
localized to punctate nuclear structures (Fig. 2B, f). P300
localized to punctate nuclear structures that co-localized with
the nuclear IRF-3 (Fig. 2B, i). Similar co-localization results
were obtained when the CBP antibody was used (Fig. 2C). In
the presence of d106 co-infection, CBP localized to punctate
dots that co-localized with IRF-3 (Fig. 2C, i). This particular
CBP antibody did not specifically stain the nucleus of the cells
(Fig. 2C, a, b), but it was able to react with CBP byWestern blot
and immunoprecipitate CBP (not shown). In total, each IRF-3-containing nuclear structure also contained p300 and CBP.
Therefore, it appeared that ICP0 co-localized with a fraction of
activated IRF-3, and that IRF-3, in turn, co-localized with CBP
and p300. Thus, ICP0 did not appear to disrupt IRF-3 and CBP/
p300 association.
Treatment with MG132 prevents the d106-induced loss of
IRF-3
ICP0 is known to influence the degradation of numerous
cellular proteins. In addition, it has been demonstrated that the
RING domain of ICP0 is required for the inhibition of IRF-3
activity (Lin et al., 2004). To determine if the loss of nuclear
IRF-3 was dependent on proteasomal activity, we performed
infections in the presence or absence of a proteasomal inhibitor
MG132. In the absence of MG132, SeV infection caused an
increase in the nuclear accumulation of IRF-3 (Fig. 3b), while
co-infection with d106 inhibited efficient IRF-3 nuclear
accumulation (Fig. 3c). However, in the presence of MG132,
the level of nuclear IRF-3 found in cells infected with SeV and
d106 was approximately equal to that of cells infected with
SeV alone (Fig. 3d). MG132 treatment also prevented the
localization of ICP0 to punctate structures, causing it to be
diffuse (Fig. 3h). These data indicated that proteasomal activity
Fig. 3. Effect of MG132 on nuclear accumulation of IRF-3. Infection of HEC-1-B cells was carried out as before, only this time the proteasomal inhibitor MG132 was
added to selected infections. MG132 (10 μM) was added at 1 hpi and maintained in the medium until fixation at 6 hpi. The cells were stained with mouse anti-IRF-3
and rabbit anti-ICP0 antibodies followed by appropriate secondary antibodies.
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accumulation.
Association of ICP0 with activated IRF-3 and CBP/p300 at
early times post-infection
To investigate if ICP0 associated with CBP and IRF-3 in
infected cells, we performed immunoprecipitation experiments
with lysates from HEC-1-B cells infected by SeV with or
without d106 co-infection. We observed that IRF-3 co-
precipitated with the CBP immune complex when cells were
infected with SeV alone (Fig. 4, lane 8), but not in mock-
infected cells (lane 7). However, when cells were infected withFig. 4. Association of ICP0 with CBP and IRF-3 in infected cells. HEC-1-B cells
were infected with the indicated viruses (SeV and/or d106) and harvested at
4 hpi. Shown is the Western blot analysis of proteins immunoprecipitated using
polyclonal antibodies against CBP or IRF-3. Lanes 1–6 show a sample of the
whole cell lysate (5% total). The arrow indicates a cellular protein band that
cross-reacts with the CBP antibody. Lanes 7–9 are lanes with proteins
immunoprecipitated using an anti-CBP antibody. Lanes 10–12 are lanes with
proteins immunoprecipitated using an anti-IRF-3 antibody. The blot was probed
with antibodies specific for CBP (top panel), ICP0 (middle panel) or IRF-3
(lower panel).both SeV and d106, we observed both ICP0 and IRF-3 in the
immunoprecipitate (Fig. 4, lane 9). When we immunoprecipi-
tated IRF-3 from infected cell extracts (Fig. 4, lanes 10–12), we
observed that the IRF-3 antibody was able to immunoprecipitate
a complex that contained CBP from SeV-infected cell lysates
(lane 11), but not from mock-infected lysates (lane 10). In
addition, both ICP0 and CBP associated with IRF-3 following
IRF-3 immunoprecipitation from the lysates of cells co-infected
with SeV and d106 (lane 12). The co-immunoprecipitation
between these proteins was not disrupted by the addition of
ethidium bromide or DNase treatment of the immunoprecipita-
tion reaction (not shown), indicating that the association was not
via DNA. These data argued that associations between ICP0 and
activated IRF-3 and CBP/p300 could explain the recruitment of
these proteins to ICP0-containing foci.
IRF-3 co-localizes with ICP0 expressed from a transfected
plasmid
To determine if ICP0, in the absence of any other SeV or
HSV-1 proteins, could recruit activated IRF-3, we transfected
cells with a plasmid expressing ICP0. To ensure that proteins
produced by SeV were not affecting ICP0 activity, we activated
IRF-3 using polyinosinic–polycytidylic acid (poly I:C), an
artificial mimic of double-stranded RNA treatment (Wathelet et
al., 1988). At 18 h after HEC-1-B cells were transfected with an
ICP0-expressing plasmid, the cells were treated with poly I:C.
Treatment with poly I:C led to the activation of IRF-3 in about
30% of the cells (Fig. 5b). Transfection with the ICP0-
expressing plasmid alone did not lead to the activation of
IRF-3 so there was no co-localization between the two proteins
(Fig. 5k). Much of the IRF-3 activated by poly I:C in the
presence of ICP0 localized to distinct nuclear foci (Fig. 5d).
These foci localized with or near the nuclear ICP0 foci (Fig. 5f).
Fig. 5. Change of IRF-3 localization in the presence of ICP0 only. HEC-1-B cells were transfected with an ICP0-expressing plasmid at 18 h prior to treatment. The cells
were treated with poly I:C (100 μg/ml) in the presence or absence of transfected ICP0. The cells were fixed at 4 h post treatment and stained with mouse anti-ICP0 and
rabbit anti-IRF-3 antibodies followed by appropriate secondary antibodies.
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were required for the co-localization of ICP0 and IRF-3. In
addition, these data argued that the association between ICP0
and IRF-3 was not an artifact of SeV co-infection.
Activation of IRF-3 is required for co-localization
Non-activated IRF-3 is in a conformation thought to be
folded upon itself, hiding the domains required for IRF-3
dimerization and DNA binding. This non-active form of IRF-3
shuttles in and out of the nucleus (Lin et al., 1998, 1999;
Yoneyama et al., 1998). To determine if IRF-3 needs to be
activated to co-localize with ICP0, we treated infected cells with
an inhibitor of IRF-3 nuclear export, leptomycin B (LepB),
which causes nuclear accumulation of non-activated IRF-3
(Karpova et al., 2002).
Cells were transfected with plasmids expressing IRF-3 or
both ICP0 and IRF-3, treated with LepB (Fig. 6, right
panels) or left untreated (left panels), and infected with SeV
as indicated. In cells transfected with IRF-3 alone, IRF-3
localized mostly to the cytoplasm (Fig. 6i). In cells treated
with LepB, IRF-3 localized strongly to the nucleus, but
there was still a considerable amount in the cytosol (Fig.
6m). SeV infection increased the amount of IRF-3 found inthe nucleus of LepB treated cells (Fig. 6n). The nuclear
IRF-3 induced by LepB treatment did not co-localize with
ICP0 (Fig. 6o). This nuclear IRF-3 was diffuse and did
not localize to distinct nuclear structures. In contrast,
ICP0 and IRF-3 co-localized when IRF-3 was activated
by SeV infection (Fig. 6t and x). These data supported
the hypothesis that IRF-3 must be activated to co-localize
with ICP0.
Activated IRF-3 co-localizes with ICP0 in HSV-1-infected cells
To ensure that the association between ICP0 and IRF-3
occurs during wild-type HSV-1 infection, we used a cell type,
human BJ fibroblasts, in which HSV-1 can activate the
interferon response (Preston et al., 2001), and we used
immunofluorescence microscopy to view the localization of
IRF-3 and ICP0 in BJ fibroblasts infected under a variety of
conditions. Mock-infected cells showed a cytoplasmic localiza-
tion of IRF-3 (Fig. 7a). In BJ fibroblasts infected with wt-HSV-1,
we observed no nuclear accumulation of IRF-3 (Fig. 7b). We
did observe ICP0 production and localization to the cytoplasm
(Fig. 7g). The addition of CHX at the time of HSV-1 infection
blocked viral protein expression (Fig. 7h), which allowed
activation of IRF-3 (Fig. 7c).
Fig. 6. ICP0 co-localizes only with activated IRF-3. HEC-1-B cells were infected with SeV (indicated at the top of the columns) or mock-infected. Cells transfected with IRF-3 (pcDNA-IRF-3) and ICP0 (pICP0)
expression plasmids were infected at 18 h following transfection. Cells were treated with leptomycin B (LepB) for 2 h before infection (right panels). LepB levels were maintained during and after infection. Cells infected
with SeV were fixed at 3 h after infection and stained with mouse anti-ICP0 and rabbit anti-IRF-3 anitbodies followed by appropriate secondary antibodies.
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Fig. 7. Localization of IRF-3 to early sites of viral replication. HEp-2 cells were infected with wild-type HSV-1 (KOS) in the presence or absence of cycloheximide
treatment (50 μg/ml). The CHX treatment was either maintained throughout infection (KOS+) or removed and replaced with normal media at 3.5 hpi (mock and
KOS+/−). At 6 hpi or mock treatment, the cells were stained with mouse anti-ICP0 and rabbit anti-IRF-3 antibodies followed by appropriate secondary antibodies.
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varied the infection conditions so that we would see IRF-3
activation as well as ICP0 production. To do this, we infected
cells with HSV-1 in the presence of CHX for 3.5 h, then
removed the CHX to allow translation to take place for 2.5 h.
Mock-infected cells treated with CHX did not show IRF-3
activation after CHX removal (Fig. 7d). In the HSV-1-
infected cells, we observed IRF-3 activation and ICP0 pro-
duction (Fig. 7, e and j). A large portion of the activated
IRF-3 co-localized with the ICP0 foci (Fig. 7o). Thus,
activated IRF-3 co-localized with ICP0 in HSV-1 infected
cells. This recruitment required IRF-3 to be activated, as no
recruitment was seen in cells infected with HSV-1 in the
absence of CHX.
Residues 680–720 of ICP0 are required for inhibition of IRF-3
nuclear accumulation
To define the domains of ICP0 needed for IRF-3 inhibition,
we tested several nonsense mutant forms of ICP0 (Cai et al.,
1993; Cai and Schaffer, 1992). Immunofluorescence micro-
scopy was performed at 6 hpi to determine the levels and
localization of IRF-3 in cells infected with the various viruses.
Co-staining with ICP8 antibody was performed to verify virus
infection. Of the nonsense mutants tested, only n720 and n770
blocked IRF-3 nuclear accumulation like wild-type HSV-1 (Fig.8f and g). All of the other mutants, while they were able to infect
cells and produce ICP8 (Fig. 8i to l), were not able to inhibit the
nuclear accumulation of IRF-3 (Fig. 8b to e). In most of these
cases, the nuclear IRF-3 co-localized with ICP8 (Fig. 8b to d),
while co-infection with n680 led to a diffuse nuclear IRF-3
localization (Fig. 8e).
Thus, residues 680–720 of ICP0 are required for the
inhibition of IRF-3 nuclear accumulation. This portion of
ICP0 contains a region required for localization of ICP0 to
ND10 foci (Ciufo et al., 1994).
To determine if n680 ICP0 also lacked the ability to
localize to nuclear structures, we characterized the ICP0
nonsense mutants for their ability to co-localize with IRF-3 at
an early time post-infection. Following HSV-1 infection of
HEp-2 cells, a very small percentage of the cells showed IRF-
3 activation. Thus, in HEp-2 cells infected with wt HSV-1,
we observed IRF-3 activation in only approximately 1–3% of
the cells. In the cases where IRF-3 was activated, it
accumulated in the nucleus and localized to punctate
structures (Fig. 9c). These structures co-localized with the
nuclear ICP0 (Fig. 9o). We observed that the n680 ICP0 did
not co-localize with IRF-3 at early times post-infection (Fig.
9p). In this case, the ICP0 did not localize to punctate
structures in the nucleus (Fig. 9j). Thus, localization of ICP0
to nuclear foci correlates with its inhibition of IRF-3 nuclear
accumulation.
Fig. 8. Effect of ICP0-mutant virus infection on IRF-3 nuclear accumulation. HEC-1-B cells were infected with SeV in the presence of a panel of ICP0 nonsense mutant viruses (n212, n428, n525, n680, n720, or n770).
The cells were fixed at 6 h post co-infection and stained with mouse anti-IRF-3 and rabbit anti-ICP8 antibodies followed by appropriate secondary antibodies. Shown also is the merged image.
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Fig. 9. Effect of ICP0-mutant virus infection on localization of activated IRF-3. HEp-2 cells were infected with either SeV, HSV-1 (KOS strain), or n680. The cells were
fixed at 2.5 hpi and stained with mouse anti-ICP0 and rabbit anti-IRF-3 antibodies followed by appropriate secondary antibodies. Shown also is the merged image.
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Various proteins are recruited to ICP0-containing bodies in
the infected cell nucleus (Burch and Weller, 2004; Everett,
2000; Hagglund and Roizman, 2004). To examine the
specificity of the recruitment of CBP/p300 to activated IRF-3
in the nuclear foci, we looked at the localization of other
members of the IFN-β transcriptional complex. Both NF-κB
(p65 subunit) and a member of the AP-1 complex, ATF2, are
activated following SeV infection and form a complex with
activated IRF-3 and CBP/p300 to cooperatively enhance the
transcription of the IFN-β gene (Merika and Thanos, 2001).
In cells co-infected with SeV and HSV-1, we observed that
IRF-3 localized to the nucleus and co-localized with ICP0 (Fig.
10g). However neither NF-κB (Fig. 10e) nor ATF2 (Fig. 10f)
co-localized with IRF-3; instead, they were localized diffusely
throughout the nucleus. If NF-κB or ATF2 were being recruited
to ICP0 foci, we would have expected to see a co-localization
with IRF-3.
In the absence of ICP0, activated IRF-3 is segregated from the
host cell chromatin during HSV-1 infection
We have shown that ICP0-mutant viruses are still able to
inhibit IRF-3 activity induced by SeV infection (Melroe et al.,
2004). There are multiple ways by which this inhibition may
occur. We therefore used immunofluorescence microscopy to
determine the localization of IRF-3 at later times after infection.Histone H1 antibody staining was used as a marker for the
location of host cell chromatin. In mock-infected cells, histone
staining was primarily nuclear (Fig. 11e), while IRF-3 staining
was cytoplasmic (Fig. 11a). Following SeV infection, IRF-3
entered the nucleus and co-localized with histones (Fig. 11j). In
cells infected with both SeV and HSV-1, we observed a loss of
nuclear IRF-3 (Fig. 11c) and marginalization of the histones to
the periphery of the nucleus (Fig. 11g). Co-infection with the
ICP0-mutant virus (7134) did not lead to a loss of nuclear IRF-3
(Fig. 11d). Instead, IRF-3 localized to viral replication
compartments, segregated from the host cell histones (Fig. 11).
Discussion
HSV ICP0, in addition to functioning as a promiscuous
transcriptional transactivator (Everett, 1984; Gelman and
Silverstein, 1985; Nabel et al., 1988; O'Hare and Hayward,
1985; Quinlan and Knipe, 1985), has been shown to play a
central role in the resistance of HSV-1 to interferon-mediated
anti-viral activity (Harle et al., 2002; Mossman et al., 2000).
What is not known, however, is the mechanism by which ICP0
performs this function. We had previously shown that ICP0 can
block nuclear accumulation of IRF-3 and IFN-β induction
(Melroe et al., 2004). We demonstrate here that ICP0 associates
with both CBP/p300 and IRF-3 following the activation of
IRF-3. We observed that activated IRF-3 enters the nucleus, co-
localizes with ICP0, and then becomes destroyed in a
proteasomal-dependent fashion. This series of events is seen
Fig. 10. Localization of members of the enhanceosome complex. HEC-1-B cells were transfected with a plasmid expressing IRF-3. At eighteen hours after
transfection, the cells were infected with HSV-1 (KOS strain) and SeV. The cells were fixed at 3 hpi and stained with mouse anti-IRF-3 (a to c) and rabbit anti-ICP0 (d),
-NF-κB (p65 subunit) (e), or -ATF2 (f) antibodies followed by appropriate secondary antibodies. Shown also is the merged image.
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IRF-3 activation. These data therefore argue that one possible
mechanism by which ICP0 inhibits the efficient transcription of
interferon is by recruiting activated IRF-3 and CBP away from
host cellular promoters at early times after infection and then
promoting their inactivation. This inhibition could be due to the
degradation of IRF-3 and/or an undefined ICP0-dependent post-
translational modification of IRF-3 or CBP/p300.
Recruitment of activated IRF-3 to nuclear ICP0 sites
The co-localization and association of activated IRF-3 and
ICP0 that we have observed suggests that it is possible that IRF-
3 is associating directly with ICP0. Another possibility is that
IRF-3 is interacting with another protein recruited to ICP0-
containing foci. We speculate that the efficient recruitment
ability of ICP0 depends on at least two domains: the RING
domain and the C-terminal multimerization domain. The RING
family of zinc finger domains have been reported to play a role
in the formation of large multi-protein complexes (Matthews
and sunce, 2002).
Lin et al. (2004) reported that the RING finger domain is
required for the efficient inhibition of IRF-3 by ICP0,
although they see, at most, a fivefold inhibition of IRF-3activity. Disruption of the RING finger domain ablates nearly
all functions of ICP0 measured to date; therefore, the finding
that it is required for the nhibition of IRF-3 could be expected
(Everett, 2000).
ICP0 localizes to PML-containing ND10 domains at early
times of infection (Everett and Maul, 1994; Maul and Everett,
1994; Maul et al., 1993). However, IRF-3 has never been shown
to accumulate at these domains following activation. Due to the
large quantities of CBP at ND10 domains (LaMorte et al.,
1998), it is possible that IRF-3 normally localizes transiently to
these foci after activation. Therefore, the possibility exists that
PML, the scaffold of ND10 domains, is required for the efficient
association between ICP0 and IRF-3. We believe this require-
ment for PML is unlikely for two reasons: (i) we observed that
the association between ICP0 and IRF-3 occurs after the
destruction of PML and (ii) others have reported that ICP0 can
form non-ND10-associated foci (Everett et al., 1999; Morency
et al., 2005).
In our immunofluorescence studies we do not see a total
sequestration of activated IRF-3 with ICP0 at early times after
infection, arguing for a case of gradual recruitment. One
possible reason for the diffuse localization is that the amount of
nuclear IRF-3 could be higher than the amount of nuclear ICP0
at very early times after infection. It may take time for ICP0 to
Fig. 11. Sequestration of IRF-3 in cells infected with an ICP0 mutant. HEC-1-B cells were infected with various virus combinations as indicated at the top of each
column. At 6 hpi or mock treatment, the cells were fixed and stained with mouse anti-histone H1 and rabbit anti-IRF-3 antibodies with appropriate secondary
antibodies.
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where IRF-3 is diffuse throughout the nucleus could explain the
observation that ICP0 only inhibits the activity of IRF-3 by, at
most, fivefold (Lin et al., 2004). Alternatively, it is still possible
that the diffuse ICP0 is interacting with the diffuse IRF-3. In the
context of cellular infection, these early interactions may be
enough to give HSV-1 the head start it needs to replicate and
spread. Thus, the spatial and temporal regulation of ICP0 and
IRF-3 are important factors to consider.
We observed that CBP/p300 can be found in the complex
that contains both ICP0 and IRF-3. Recently it has been
reported that the bovine herpesvirus 1 bICP0 protein interacts
with p300 (Zhang et al., 2006). The histone deacetylase and
scaffolding functions of CBP and p300 are very important
for the efficient transcription of numerous cellular proteins
(Chan and La Thangue, 2001; Kalkhoven, 2004). Reducing
the amount of CBP available for cellular transcription may
help to create an environment more suitable for HSV-1
replication. As stated previously, CBP/p300 is thought to be
used by HSV-1 during infection (Herrera and Triezenberg,
2004). Our findings support the possibility that there is
competition for these transcription factors following IRF-3
activation.
Physical separation of IRF-3 from the host chromatin is also
observed when cells are infected with an ICP0 mutant virus.
This altered localization may play a role in the inhibition ofinterferon transcription seen previously (Melroe et al., 2004).
These results complement previous work in that they provide an
explanation as to how HSV-1 can inhibit IRF-3 activity in the
absence of ICP0.
The ability to recruit IRF-3 to nuclear sites away from
cellular chromatin is a new mechanism by which ICP0 can
inhibit or alter the function of select cellular proteins. ICP0
has been shown to recruit other cellular proteins without
greatly affecting their stability (Burch and Weller, 2004).
Hence, it is likely that the RING finger domain of ICP0
functions as a domain promoting the formation of larger
complexes. The evidence that neither NF-κB (p65) nor ATF2
co-localize with the activated IRF-3 in ICP0-foci argue
against the non-specific recruitment of proteins to this area.
The question remains as to how ICP0 is able to specifically
recruit certain cellular proteins while excluding others.
Identification of more proteins that localize to these structures
may give a better picture of the function of these domains and
this specificity.
Degradation of activated IRF-3 is promoted by ICP0
Following the dsRNA-induced activation of IRF-3, degrada-
tion occurs in a proteasomal-dependent fashion as a means to
attenuate the immune response (Lin et al., 1998; Saitoh et al.,
2006). During HSV-1 infection, following the recruitment of
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regulation of IRF-3. ICP0 is likely using its E3 ubiquitin–ligase
activity to positively influence the ubiquitination and degrada-
tion of IRF-3 using the host proteasomal machinery. The
reported presence of the proteasomal proteins in ICP0-contain-
ing foci may explain the higher rate of degradation of select
cellular proteins (Burch and Weller, 2004).
Alternate explanations for the inhibition of nuclear accumu-
lation is that the association of IRF-3 with ICP0 may result in a
post-translational modification that would send IRF-3 back to
the cytoplasm, thus reducing the nuclear levels or ICP0 may
shuttle IRF-3 to the cytoplasm. A similar situation is seen when
IRF-3 is activated in the absence of DNA-PK in some cells
(Karpova et al., 2002).
The localization of nuclear IRF-3 during infection with an
ICP0-mutant virus helps to explain how HSV-1 inhibits the
activity of IRF-3 in the absence of degradation. The incorpora-
tion of IRF-3 into replication compartments during DNA
replication would make it unavailable to promote the transcrip-
tion of interferon at later times. IRF-3 may be able to promote
transcription at earlier times, before the formation of replication
compartments. It is likely that the vhs protein would destroy
these transcripts (Elgadi and Smiley, 1999; Lin et al., 2004;
Strelow and Leib, 1995). In addition, it is possible that this
replication compartment-associated IRF-3 negatively affects
HSV-1 replication.
The failure of the n680 mutant to inhibit IRF-3 nuclear
accumulation suggests that association with ND10 nuclear
structures is a necessary prerequisite for IRF-3 inhibition.
Another study tested a variety of ICP0 mutants, including
C-terminal truncation mutants containing only the first 593
residues of ICP0, and observed that the only region of ICP0
required for the inhibition of IRF-3 activity is the N-terminal
RING finger domain (Lin et al., 2004). If ICP0–IRF-3
association is required for efficient inhibition of interferon
production, why are C-terminal mutants still able to inhibit
IRF-3 activity? The answer may lie in the ways the experiments
were conducted. In transfection systems, there is a lot more
ICP0 present than what is found in infected cells. This is
especially true for cells infected with a virus at a low
multiplicity of infection when the defect found in ICP0
mutants is most apparent. Furthermore, in transfected cells,
the ICP0 has been present for a much longer time, amplifying
its possible deleterious effects on the cell. Therefore, we
believe that in infected cells, the multimerization/ND10
localization domain of ICP0 is required for optimal ICP0
inhibition of IRF-3 activity. However, this requirement may not
be apparent in a transfection situation.
Our proposed mechanism by which ICP0 inhibits IRF-3
activity may be a common scheme used by other proteins as
well. It has been recently shown that the host Pin1 protein will
specifically interact with activated IRF-3 and, following an
induced conformational change, make IRF-3 more susceptible
to destruction (Saitoh et al., 2006). The rotavirus NSP1 protein
has been shown to associate with IRF-3 by yeast two-hybrid
(Graff et al., 2002) and this association leads to the increased
degradation of activated IRF-3 (Barro and Patton, 2005).Overall, the presence of the NSP1 protein is responsible for the
inhibition of interferon production.
These results provide insight into the sequestration ability of
ICP0 and how it contributes to the inhibition of the innate
immune response. Recruitment of activated IRF-3 and CBP/
p300 and accelerated degradation of IRF-3 joins the growing
list of reported functions of ICP0 and allows us to hypothesize a
mechanism by which ICP0 inhibits IRF-3 function and creates a
favorable environment for viral transcription and replication.
Materials and methods
Cells and viruses
Human endometrial adenocarcinoma (HEC-1-B), BJ fibro-
blast, and HEp-2 cells were obtained from the American Type
Culture Collection (Manassas, VA) (ATCC numbers HTB-113,
CRL-2522, and CCL-23, respectively). The cells were grown as
monolayer cultures in Dulbecco's modified Eagle's medium
(DMEM; Invitrogen) supplemented with 5% heat-inactivated
bovine calf serum (HyClone), penicillin (100 U/ml), and
streptomycin (100 μg/ml) in a humidified 5% CO2 atmosphere
at 37 °C.
The HSV-1 wild-type (wt) KOS virus strain was propagated
and titrated as described previously (Knipe and Spang, 1982).
The 7134 (ICP0 null) virus (Cai and Schaffer, 1989) and the
ICP0 nonsense mutants (n212, n428, n525, n680, n720, and
n770) were described in the indicated references. The HSV-1
d106 virus has been described elsewhere (Samaniego et al.,
1998). Sendai virus (SeV) Cantel strain was obtained from
Charles River SPAFAS (Wilmington, MA).
Plasmids and antibodies
The ICP0 expression vector (pICP0) was constructed by
inserting the KpnI fragment from pSG1-ES1 (Quinlan and
Knipe, 1985) containing the ICP0 gene into pUC19 (New
England Biolabs, Beverly, MA). The IRF-3 expression vector
was provided by Peter Howey (Harvard Medical School,
Boston, MA). Transfections were carried out using Lipofecta-
mine 2000 following the manufacturer's protocol (Invitrogen,
San Diego, CA).
Mouse monoclonal antibodies were used as follows: Anti-
ICP0 (5H7-East Coast Biologics, Inc., North Berwick, ME)
used at 1:200 dilution for immunofluorescence, and 1:1000
dilution for Western blots. Anti-IRF-3 (SL12.1-BD PharMin-
gen, San Diego, CA) used at 1:100 for immunofluorescence and
at 1:1000 for Western blots. Anti-CBP (C-1-Santa Cruz
Biotechnology, Inc., Santa Cruz, CA) used at 1:50 for
immunofluorescence. Anti-CBP (AC238, provided by James
DeCaprio, Dana Farber Cancer Institute, Boston, MA) used at
1:10 for immunofluorescence. Anti-p300 (RW128, provided by
James DeCaprio, Dana Farber Cancer Institute, Boston, MA)
used at 1:10 for immunofluorescence.
Rabbit polyclonal antibodies were used as follows: Anti-
ICP0 (provided by Bernard Roizman, The University of
Chicago, Chicago, IL) used at 1:1000 for immunofluorescence.
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Cruz, CA) used at 1:50 for immunofluorescence. Anti-CBP
(A-22-Santa Cruz Biotechnology, Inc., Santa Cruz, CA) used at
1:50 for immunofluorescence, and 1:500 dilution for Western
blots. Anti-ICP8 (3-83; (Knipe et al., 1987) used at 1:200 for
immunofluorescence. Anti-p300 (N-15-Santa Cruz Biotechnol-
ogy, Inc., Santa Cruz, CA) used at 1:50 for immunofluores-
cence. Anti-NF-κB p65 (C-20-Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA) used at 1:50 for immunofluorescence. Anti-
ATF2 (C-19-Santa Cruz Biotechnology, Inc., Santa Cruz, CA)
used at 1:50 for immunofluorescence.
Viral infections
HEC-1-B cells were plated into 24-well culture dishes on
12 mm circle cover glass (for immunofluorescence), 100 mm
culture dishes (for immunoprecipitation), or 6-well culture
dishes (for Western blot) 24 h prior to infection to obtain 90%
confluence at the time of infection. Cells were infected with
either wild-type or mutant HSV-1 virus strains at a multiplicity
of infection of 20 plaque-forming units (PFU, as titrated on Vero
cells (KOS) or E-11 cells (d106)) per cell in cold phosphate-
buffered saline (PBS) containing 0.1% glucose and 1% heat-
inactivated fetal bovine serum. As indicated, cells were infected
with 100 hemagglutination units (HAU)/ml of SeV (as
determined by Charles River Labs). After 1 h of adsorption at
37 °C, cells were overlaid with Dulbecco's modified Eagle's
medium containing 1% heat-inactivated fetal bovine serum and
maintained at 37 °C.
Immunofluorescence
For indirect immunofluorescence, HEC-1-B monolayers
were fixed for 15 min in PBS with 3.7% formaldehyde and
permeabilized for 2 min with ice-cold methanol. Alexa Fluor
488- or Alexa Fluor 594-conjugated goat anti-rabbit or goat
anti-mouse secondary antibodies (Molecular Probes, Eugene,
OR) were used at a 1:1000 dilution. Coverslips were mounted
on glass slides in ProLong antifade agent (Molecular Probes,
Eugene, OR). Images were obtained with a Zeiss Axioplan 2
microscope using a Hamamatsu digital camera (C4742-95) and
OpenLab software (version 3.1.7; Improvision, Lexington,
MA).
Immunoprecipitation and Western blot analyses
Cells were harvested by scraping into media. After two
washes in cold PBS, cells from each dish were incubated on ice
for 30 min in 1 ml of immunoprecipitation (IP) lysis buffer
(20 mM Tris–HCl [pH 7.5], 50 mM NaCl, 0.1% NP-40, 10 mM
β-glycerophosphate, 5 mM NaF, 1 mM PMSF, 2.5% glycerol,
and 1 Complete mini protease inhibitor cocktail tablet [Roche
Applied Science, Indianapolis, IN] per 10 ml). Cell lysates were
clarified by centrifugation at 10,000×g at 4 °C for 5 min, and
precleared overnight by incubating with protein A-agarose
beads at 4 °C. A total of 40 μl of precleared lysate was set aside,
and immunoprecipitation was carried out with either thepolyclonal IRF-3 or CBP antibody (1:50 dilution) and protein
A-agarose beads at 4 °C for 2–4 h. After four washes in washing
buffer (20 mM Tris–HCl [pH 7.5], 50 mM NaCl, 0.1% NP-40,
and 1 mM PMSF), the immunoprecipitates were dissolved in
gel sample buffer (Knipe and Spang, 1982) for separation by
sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS–PAGE) in a 9% bis-crosslinked polyacrylamide gel.
After electrophoresis, the proteins were transferred onto a
nitrocellulose membrane (Protran; Schleicher and Schuell
Bioscience, Keene, NH) by electroblotting at 40 V overnight.
The membranes were blocked in 5%milk in Tris-buffered saline
(TBS), probed for the appropriate antibody in TBS containing
0.1% Tween 20, and stained with enhanced chemiluminescence
(ECL) Western blotting detection reagents (PerkinElmer,
Boston, MA) in accordance with the manufacturer's protocol.
Western blot for IRF-3 levels
Cells were harvested at various time points post-infection by
scraping into media. After two washes in cold PBS, cells from
each well were incubated on ice for 30 min in immunopreci-
pitation (IP) lysis buffer. Cell lysates were clarified by
centrifugation at 10,000×g at 4 °C for 5 min, and the resulting
extract was dissolved in gel sample buffer (Knipe and Spang,
1982) for separation by sodium dodecyl sulfate–polyacryla-
mide gel electrophoresis (SDS–PAGE) in a 9% bis-crosslinked
polyacrylamide gel. Protein transfer and blotting was performed
as described above.
Quantification of relative cellular levels of IRF-3 and DNA-
PKcs by measurement of intensity of Western blot staining has
been described previously (Melroe et al., 2004). Briefly, the
developed film was converted into a high-resolution digital
image (UMAX scanner UTA-MII). The intensity of each band
was determined by using image-scanning densitometer software
(ImageQuant TL; GE Healthcare, Piscataway, NJ).
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